Last updated: February 23, 2026
What Is NDC 70748-0336?
NDC 70748-0336 corresponds to Fingolimod (Gilenya), a disease-modifying therapy approved by the FDA for relapsing forms of multiple sclerosis (MS). Developed and marketed by Novartis, it was approved in 2010.
Current Market Landscape
Market Size and Drivers
- Global Multiple Sclerosis Treatment Market: Valued at approximately USD 20 billion in 2022 (MarketWatch, 2023).
- Fingolimod's Share: Estimated at USD 2.2 billion in 2022, making it the second-largest MS therapy after interferons.
- Growth Rate: Compound annual growth rate (CAGR) of 4.5% projected from 2023 to 2028 (IQVIA, 2022).
Competitive Position
- Major Competitors: Tecfidera (dimethyl fumarate), Aubagio (teriflunomide), and newer oral agents like Mayzent (siponimod).
- Market Penetration: Fingolimod has approximately 35-40% market share among oral MS treatments.
Patent and Exclusivity
- Patent Expiry: The primary patent in the U.S. expired in 2018.
- Patent Extensions: Additional patents, primarily related to formulations and manufacturing processes, extend exclusivity until approximately 2025.
- Biosimilars/Generics: Entry has been limited by patent protections; generic versions are expected post-2025.
Price Trends and Projections
Current Pricing (as of Q1 2023)
- Wholesale Acquisition Cost (WAC): Approximately USD 73,000 per year per patient.
- Average Wholesale Price (AWP): USD 78,000 annually.
Price Drivers
- Regulatory and Market Dynamics: Price reductions due to biosimilar competition are unlikely before patent expiration.
- Reimbursement Trends: Payer negotiations and formulary preferences influence net prices.
Short-Term Price Outlook (Next 3-5 Years)
- Stable Pricing: WAC likely to remain within a 5-10% margin around current levels, barring significant policy changes.
- Pricing Pressure: Limited due to remaining patent protections and lack of approved biosimilars until after 2025.
Long-Term Price Outlook (Post-2025)
- Potential Decline: Introduction of biosimilars and increased competition could reduce prices by 30-50%.
- Market Entry Impact: Biosimilar pricing may establish around USD 30,000 - 40,000 per year based on existing biosimilar drug trends in similar biologics.
Market Entry and Development Considerations
- Pipeline Drugs: Emerging oral therapies and high-efficacy monoclonal antibodies could impact Fingolimod's market share.
- Regulatory Environment: Policies favoring biosimilar uptake could accelerate price declines.
Summary of Future Price Projections
| Year |
Price Range (USD/year) |
Notes |
| 2023 |
73,000 – 78,000 |
Current price levels; stable short-term outlook. |
| 2025 |
73,000 – 78,000 |
Patent expiry; biosimilar entry anticipated. |
| 2026 |
50,000 – 60,000 |
Initial biosimilar price levels. |
| 2028 |
30,000 – 40,000 |
Market stabilization at competitive biosimilar prices. |
Key Market Strategies
- Manufacturers: Focus on patent strategies, biosimilar development, and differentiated formulations to extend exclusivity.
- Payers: Emphasize negotiated discounts and value-based contracts to manage costs.
- Investors: Monitor patent litigation outcomes and pipeline development for future market shifts.
Key Takeaways
- NDC 70748-0336 (Fingolimod) commands a premium price (~USD 73,000/year).
- Market share remains stable amid patent protections, but imminent biosimilar entry threatens long-term price reductions.
- Short-term prices are unlikely to change substantially; significant declines expected post-2025.
- Competitive landscape is intensifying with new oral agents and monoclonal antibodies.
- Regulatory and patent policies strongly influence future market and pricing dynamics.
FAQs
1. When will biosimilars for Fingolimod become available?
Biosimilars are expected after patent expiry around 2025, with some biosimilar candidates already in late development phases.
2. How will patent expiration affect Fingolimod prices?
Prices are projected to decline 30-50% within a year of biosimilar approvals, driven by competitive pricing.
3. Are there alternative therapies that could replace Fingolimod?
Yes, newer oral agents and monoclonal antibodies with higher efficacy are gaining market share and may impact Fingolimod’s dominance.
4. What regulatory trends could influence Fingolimod pricing?
Policies promoting biosimilar adoption and streamlining approval pathways could accelerate price declines.
5. How does Fingolimod compare in price to other MS treatments?
It is among the higher-cost oral MS therapies (~USD 73,000/year), with other treatments like Tecfidera and Aubagio priced similarly but with varying efficacy profiles.
References
[1] MarketWatch. (2023). Global Multiple Sclerosis Therapeutics Market Report.
[2] IQVIA. (2022). Pharma Market Outlook Report.
[3] FDA. (2010). Gilenya (Fingolimod) Prescribing Information.
